Physician profile
Michael A Geile
NPI 1861499022
$4,147.73
in general payments reported to CMS, 2019-2025
39 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $312 · 2022: $290 · 2023: $547 · 2024: $862 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $904.40 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $444.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $418.36 | 2019-2024 | |
| Abbvie INC. | $355.71 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $211.00 | 2019-2025 | Farxiga, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $189.67 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $176.58 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.88 | 2019-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $136.47 | 2019-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $130.70 | 2022-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $110.61 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.54 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $72.16 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $62.64 | 2024-2025 | Voquezna |
| Dexcom, INC. | $58.10 | 2024-2025 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Geile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.